Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Fish and Richardson
Boehringer Ingelheim
Farmers Insurance
Healthtrust
Teva
Medtronic
AstraZeneca

Generated: December 13, 2018

DrugPatentWatch Database Preview

VIMPAT Drug Profile

« Back to Dashboard

Which patents cover Vimpat, and what generic alternatives are available?

Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-two patent family members in eleven countries.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lacosamide profile page.

Drug patent expirations by year for VIMPAT
Generic Entry Opportunity Date for VIMPAT
Generic Entry Dates for VIMPAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS
Generic Entry Dates for VIMPAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;ORAL
Generic Entry Dates for VIMPAT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for VIMPAT
( )-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide
(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide
(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide;Lacosamide
(2R)-2-acetamido-3-methoxy-N-(phenylmethyl)propanamide
(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide
(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
(2R)-2-acetylamino-N-benzyl-3-methoxypropanamide
(2R)-N-benzyl-2-acetamido-3-methoxypropanamide
(R)-2-acetamido-N-benzyl-3-methoxypropanamide
(R)-2-acetamido-N-benzyl-3-methoxypropionamide
(R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide
(R)-2-Acetylamino-N-benzyl-3-methoxypropionamide
(R)-N-benzyl 2-acetamido-3-methoxypropionamide
(R)-N-benzyl 2-acetamido-3-methoxypropionamide,
(R)-N-benzyl-2-acetamido-3-methoxypropanamide
(R)-N-Benzyl-2-acetamido-3-methoxypropionamide
175481-36-4
2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide, (2R)-
481L364
563KS2PQY5
AB0020074
AB01559947-01
AB1011880
AC-22750
AC1L560M
ADD 234037
ADD 243037
ADD-234037
ADD-243037
AJ-08306
AK-80442
AKOS005146274
AM808141
AN-5196
ANW-58547
BB 0260890
BDBM50300204
CAS-175481-36-4
CHEBI:135939
CHEMBL58323
CJ-00115
CS-0529
CTK8B7781
D05OFX
D07299
DB06218
DEA No. 2746
DSSTox_CID_31455
DSSTox_GSID_57666
DSSTox_RID_97341
DTXSID1057666
EBD27785
Erlosamide
Erlosamide [INN]
Erlosamide, Vimpat, Lacosamide
ertosamide
FT-0650739
GTPL7472
harkeroside
Harkoseride
HY-13015
I01-7424
I14-32137
KS-00000XOQ
KS-1227
Lacosamide
Lacosamide (JAN/USAN/INN)
Lacosamide (USAN/INN)
Lacosamide [USAN:INN:BAN]
Lacosamide [USAN]
Lacosamide racemate
Lacosamide solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
Lacosamide; Propanamide,2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (R)-
LS-185541
M-1600
MFCD08272557
MolPort-006-170-142
NCGC00253740-01
OR059448
OR231753
PROPANAMIDE 2-(ACETYLAMINO)-3-METHOXY-N-(PHENYLMETHYL)- (2R)-
Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
RL02246
SCHEMBL35330
SPM 927
SPM-927
SPM-929
SR-01000942286
SR-01000942286-1
ST24026403
TC-064381
Tox21_113857
UNII-563KS2PQY5
V0815
Vimpat (TN)
VPPJLAIAVCUEMN-GFCCVEGCSA-N
Z1550648754
ZINC7673

US Patents and Regulatory Information for VIMPAT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254-001 Oct 28, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for VIMPAT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-001 Oct 28, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Ucb Inc VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254-001 Oct 28, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-003 Oct 28, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for VIMPAT
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for VIMPAT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/007 United Kingdom ➤ Try a Free Trial PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
0888289/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: LACOSAMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59004 28.08.2009
C001/2009 Ireland ➤ Try a Free Trial SPC001/2009: 20091013, EXPIRES: 20220316
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
Chubb
Citi
AstraZeneca
Daiichi Sankyo
Accenture
Cantor Fitzgerald
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.